NSE · KILITCH · Pharmaceuticals
Kilitch Drugs (India) Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹72 Cr with net profit ₹14 Cr — a 19.45% net margin, versus 10.95% the period before.
Shareholding
As of 2026-06-30
- Promoter63.77%
- Public36.11%
- FII0.12%
- DII0%
12,627 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.94× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #18 of 50 by market cap · medians across 41 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,562 Cr | 84.67 | 22.07 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,434 Cr | 159.09 | 9.4 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,961 Cr | 114.27 | 4.05 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,167 Cr | 326.41 | 19.57 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,863 Cr | 116.76 | 5.54 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,767 Cr | 69.25 | 5.06 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,825 Cr | 109.73 | 4.56 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,757 Cr | 79.34 | 3.89 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,071 Cr | 165.62 | 6.5 | 12.36% | 18.32% |
| Bliss GVS Pharma Ltd. | ₹4,836 Cr | 141.61 | 4.04 | 8.95% | 11.15% |
| Kilitch Drugs (India) Ltd.(this company) | ₹651 Cr | 43.92 | 2.33 | 10.79% | 12.81% |
AI analysis
AI-generated · google/gemini-2.5-flashKilitch Drugs (India) Ltd. is listed with a market capitalization of Rs 623 Cr. The company reported revenue of Rs 209.48 Cr and a net profit margin of 12.81%. Its earnings per share (EPS) stands at Rs 8.63. The 52-week high for the share price was Rs 227.23, and the 52-week low was Rs 117.25.
Positives
- +Revenue grew by 28.5%, indicating operational expansion.
- +Promoter holding is substantial at 63.77% as of June 30, 2026.
- +Debt-to-equity ratio is low at 0.21, suggesting sound financial leverage.
- +There are no promoter shares pledged.
Negatives
- −The company has a relatively low ROE of 10.79%.
- −The trailing EPS of Rs 8.63 is lower than the annual EPS of Rs 16.6 for Mar 2025.
- −The company is under ESM surveillance (ESM Stage 1).
Financial Performance
For the fiscal year ending March 2025, Kilitch Drugs (India) Ltd. reported a revenue of Rs 209.48 Cr, demonstrating a revenue growth of 28.5%. The net profit for the same period was Rs 26.70 Cr. The company's earnings per share (EPS) was Rs 16.6 in March 2025.
Profitability & Returns
The company recorded a profit margin of 12.81%. Return on equity (ROE) for Kilitch Drugs (India) Ltd. was 10.79%, and return on capital employed (ROCE) stood at 12.00%. The EPS was Rs 8.63.
Balance Sheet
Kilitch Drugs (India) Ltd. has a debt-to-equity ratio of 0.21, indicating a relatively low level of debt. The book value per share is Rs 79.99. No dividend yield is reported for the company.
Ownership & Pledges
As of June 30, 2026, promoters held 63.77% of the shares. Public shareholding was 36.11%, while institutional investors held 0.12%. There were no promoter share pledges reported.
Regulatory & Surveillance
Kilitch Drugs (India) Ltd. is currently under ESM surveillance, specifically in ESM Stage 1. This indicates that the stock is subject to enhanced monitoring measures by the exchange.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Kilitch Drugs (India) Ltd.share price & fundamentals